Background:
To evaluate whether intracameral dexamethasone – moxifloxacin can safely and effectively reduce the postoperative inflammation, guard against endophthalmitis and improve surgical outcomes after cataract surgery.
Methods:
Prospective randomized comparative study included 200 eyes of 200 Patients underwent uncomplicated phacoemulsification . 100 eyes were injected intracamerally with 0.1 ml moxifloxacin 0.5% and 0.4 mg dexamethasone at the end of surgery while the other 100 eyes as a control group received intracameral placebo injection. Outcomes were measured on first postoperative day and weekly for one month by visual acuity assessment, slit lamp examination, intraocular pressure , endothelial cell density and any postoperative complications.
Results:
Aqueous cells on the first postoprative day in group I : five eyes had 2+, and 7 eyes had 1+ with no eyes of +3 or more. After 1 week , all eyes had no anterior chamber cells. In group II, the first postoperative day showed 11 eyes with 3+, 15 eyes had 2+, 8 eyes had 1+. One week postoperatively , only 3 eyes had +1 aquous cells. All eyes of both groups had no detected anterior chamber cells at subsequent follow up visits. The mean postoperative endothelial cell density in injectedgroup was 2274.15 cells/mm2 ±330.09. after one month . There was no significant effect on IOP values with no detected long-term complications .
Conclusion:
Intracameral dexamethasone- moxifloxacin injected at the end of cataract surgery reduces the postoperative AC cells significantly and improves patient's compliance in early postoperative follow period with no risk of IOP elevation.